24/7 Wall St. » VRTX

Top Earnings Previews For Thursday (BZH, PHM, BX, CME, DOW, GNW, GILD, IP, K, MA, MRK, RCL, HOT, TRMB, VRTX, YRCW)

Administrator — Wed, 01 Feb 2012 20:43:53 +0000

Earnings season is still upon us. There are going to be many big earnings reports Thursday and we would consider Thursday as the climax for the companies reporting their normal fourth quarter results of 2011 which have fiscal year-end dates of December 31.

We have two homebuilder earnings due from Beazer Homes USA Inc. (NYSE: BZH) and PulteGroup, Inc. (NYSE: PHM). Other key earnings to watch will be from the following: Blackstone Group L.P. (NYSE: BX); Boston Scientific Corporation (NYSE: BSX); CME Group Inc. (NYSE: CME); Dow Chemical Co. (NYSE: DOW); Genworth Financial Inc. (NYSE: GNW); Gilead Sciences Inc. (NASDAQ: GILD); International Paper Co. (NYSE: IP); Kellogg Co. (NYSE: K); MasterCard Inc. (NYSE: MA); Merck & Co. Inc. (NYSE: MRK); Royal Caribbean Cruises Ltd. (NYSE: RCL); Starwood Hotels & Resorts Worldwide Inc. (NYSE: HOT); Trimble Navigation Ltd. (NASDAQ: TRMB); Vertex Pharmaceuticals Inc. (NASDAQ: VRTX); YRC Worldwide Inc. (NASDAQ: YRCW).

We have included Thomson Reuters consensus estimates on each company. On most we have included pricing data and/or other bits of color for traders to consider.

We have two different homebuilders on deck to report. Beazer Homes USA Inc. (NYSE: BZH) is expected to post -$0.36 EPS on $211.4 million in sales and we would watch cancellation rates on contracts as well as the quality of the earnings. Second is PulteGroup, Inc. (NYSE: PHM) with an expected positive earnings of $0.07 EPS on $1.14 billion in sales. Pulte’s cancellation rates and quality of earnings will also have to be monitored.

Blackstone Group L.P. (NYSE: BX) will show private equity wealth and earnings in the morning. The firm is expected to report earnings of $0.38 EPS on revenues of $986.75 million.

Boston Scientific Corporation (NYSE: BSX) has been down and out for longer than any current and past holder would like to consider. Thomson Reuters has estimates of $0.08 EPS on $1.91 billion in sales.

CME Group Inc. (NYSE: CME) is expected to report earnings of $3.71 EPS and $754 million in sales before the market opens. With a possibility of a state-relocation and the ongoing pressure of exchange mergers we would be watching this one. At roughly $244.50, the 52-week trading range is $224.69 to $317.27.

Dow Chemical Co. (NYSE: DOW) is expected to turn in earnings of $0.30 EPS on $14.19 billion in sales. The report is due in the morning.

Genworth Financial Inc. (NYSE: GNW) is expected to report earnings of $0.19 EPS on $2.58 billion in sales. The shares are now up over 60% from the lows of the last year and the stock still remains pressured due to the mortgage insurance overhang that has been in place for quite some time.

Gilead Sciences Inc. (NASDAQ: GILD) has shocked the market by outperforming despite what appears to be a bad use of effort and capital in the large acquisition. Still, shares hit a new 52-week high on Wednesday. Thomson Reuters has estimates of $1.05 EPS and $2.18 billion in sales.

International Paper Co. (NYSE: IP) is close to being within striking range of a 52-week high and it pays well above a 3% yield today. Thomson Reuters has estimates of $0.61 EPS and $6.5 billion in sales.

Kellogg Co. (NYSE: K) is lagging and actually close to a 52-week low with shares around the $49.50 mark. The estimates are $0.63 on $2.99 billion in sales. The bar is set very low here.

MasterCard Inc. (NYSE: MA) will show just what the interchange fee problems look like, but that is not fully reflected at all in current numbers. The consensus estimates are $3.92 EPS and $1.73 billion in sales. With shares around $357 some are concerned over valuations here.

Merck & Co. Inc. (NYSE: MRK) is reporting early Thursday morning and the company’s higher dividend hike has shares trading very close to 52-week highs with a price of close to $38.70 andf a 52-week range of $29.47 to $39.43. Estimates are $0.95 EPS and $12.53 billion in sales. To show just how low growth is the estimates of $3.76 EPS and $48.23 billion in sales for all of 2011 are only expected to be $3.83 EPS on $47.62 billion in sales for all of 2012.

Royal Caribbean Cruises Ltd. (NYSE: RCL) may or may not release. With its rival’s disaster, we are not doing much legwork here. Thomson Reuters has a projection of $0.15 EPS and $1.78 billion in sales.

Starwood Hotels & Resorts Worldwide Inc. (NYSE: HOT) is key for hotel investors and this one is expected to post $0.57 EPS on $1.42 billion in sales. Starwood has over $1 billion in cash but is still trading at a high 3.7-times book value.

Trimble Navigation Ltd. (NASDAQ: TRMB) is not so widely watched on its own, but it is used as a barometer reading for Garmin. Trimble estimates are $0.48 EPS and $419.10.

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) has been in the news with new FDA approvals. We have Thursday as the tentative date and estimates are $0.73 EPS and $523.66 million in sales.

YRC Worldwide Inc. (NASDAQ: YRCW) is set to report and it is a puzzlement as to how this stock is still alive. On a reverse split basis the $12.83 price compares to a 52-week range of $7.94 to somewhere over $1,000. The consensus is listed as -$6.97 EPS but we have no idea how these targets are composed on this company.

JON C. OGG

Filed under: 24/7 Wall St. Wire, Calendar, Earnings Tagged: BX, BZH, CME, DOW, GILD, GNW, HOT, IP, K, MA, MRK, PHM, RCL, TRMB, VRTX, YRCW

Top Analyst Upgrades & Downgrades (AMZN, ASH, BAC, C, CAT, DB, XOM, MWW, NEM, STX, SXC, WBSN, VRTX)

Administrator — Wed, 01 Feb 2012 13:18:09 +0000

These are some of the top analyst upgrades, downgrades, and initiations seen from Wall Street brokerage and research firms this Wednesday morning.

Amazon.com Inc. (NASDAQ: AMZN) Maintained Neutral but cut target to $190 at Credit Suisse; Maintained Outperform but lowered estimates at Baird; Lowered target to $225 at Jefferies.
Applied Micro Circuits Corporation (NASDAQ: AMCC) Cut to Perform at Oppenheimer.
Ashland Inc. (NYSE: ASH) named as the Value Stock of the Day at Zack.
Bank of America Corp. (NYSE: BAC) named as Bear of the Day with under current price objective target by Zacks.
Citigroup, Inc. (NYSE: C) Raised to Outperform at Wells Fargo.
Caterpillar, Inc. (NYSE: CAT) named as Bull of the Day with way above-consensus price target at Zacks.
Deutsche Bank AG (NYSE: DB) Started as Outperform at Credit Suisse.
Exxon Mobil Corporation (NYSE: XOM) Cut to Hold at Argus.
Monster Worldwide, Inc. (NYSE: MWW) Cut to Perform at Oppenheimer.
Newmont Mining Corporation (NYSE: NEM) Cut to Hold at Stifel Nicolaus.
Seagate Technology plc (NASDAQ: STX) Raised to Buy at Stifel Nicolaus.
SunCoke Energy Inc. (NYSE: SXC) Reinstated as Outperform at Credit Suisse.
Websense Inc. (NASDAQ: WBSN) Cut to Market Perform at Wells Fargo.
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) Reiterated Outperform and raised target at $42 at Credit Suisse.

If you enjoyed the top analyst calls, you can sign up in the box below to join our morning email list to receive news directly in your inbox each morning. We include major analyst upgrades and downgrades, IPO and M&A news, special situation developments, observations on Warren Buffett and key market gurus, as well as special exclusive feature stories.

JON C. OGG

Filed under: 24/7 Wall St. Wire, Analyst Calls Tagged: AMZN, ASH, BAC, C, CAT, DB, MWW, NEM, STX, SXC, VRTX, WBSN, XOM

Tracking Dividends in Biotech: Who Follows Amgen in Payouts? (AMGN, PFE, MRK, BIIB, CELG, ALXN, CBST, PDLI, REGN, VRTX)

Administrator — Wed, 04 Jan 2012 13:01:10 +0000

For several years it has been the case that Amgen Inc. (NASDAQ: AMGN) was considered a biotech though it had at least some of the same problems of Big Pharma players like Pfizer Inc. (NYSE: PFE) and Merck & Co. (NYSE: MRK). The difference is that Amgen refused for ages to pay a dividend. 2011 marked a change in its dividend policy.

Amgen’s current dividend is 2.3%, which is rather high for a biotech stock. It also should be noted that the $64.00 price is above the stock’s old former rangebound levels of $50.00 to $60.00. Pfizer currently yields 3.7%, but that is about to rise to closer to 4%, and Merck yields about 4.50% after its dividend hike.

The question for 2012 is simple: Which biotech stocks will be among the second waves to initiate paying a dividend? By our count, these are the biotech outfits that might entertain following Amgen’s dividend path: Biogen Idec Inc. (NASDAQ: BIIB), Celgene Corporation (NASDAQ: CELG), Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), Cubist Pharmaceuticals Inc. (NASDAQ: CBST), PDL BioPharma, Inc. (NASDAQ: PDLI), Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), and Vertex Pharmaceuticals Inc. (NASDAQ: VRTX).

We would have evaluated the chances of Gilead Sciences Inc. (NASDAQ: GILD) initiating a dividend, but this $11 billion proposed buyout of Pharmasset, Inc. (NASDAQ: VRUS) is likely to keep Gilead tied up for quite some time.

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) is close to all-time highs above $70 and is now worth a whopping $13.2 billion. Estimates are $1.30 EPS for 2011 and $1.66 EPS for 2012, making this one have a much higher valuation while it is still rapidly growing. Some investors may expect that it could start paying out a dividend, but it is too soon by our take today, even with a $445 million balance of cash and liquidity with almost no long-term debt.

Biogen Idec Inc. (NASDAQ: BIIB) has estimates of $5.89 EPS in 2011 and $6.31 EPS in 2012. The company had only about $3 billion in cash and investments at the end of September versus a current market cap of about $27 billion. 2011 was the year that investors decided to give up on worrying about the very rare PML cases in TYSABRI, and that allowed Biogen shares to rise almost 60% in 2011. If Biogen decides to get off the no-dividend bandwagon soon, we would only look for an initial payout of $1.00 on an annualized basis for a while.

Celgene Corporation (NASDAQ: CELG) may still be too new of an earnings story to start expecting a dividend. The earnings estimates are $3.80 EPS in 2011 and $4.51 EPS in 2012. With almost $2.6 billion in cash and investments, its market cap is larger than Biogen’s at $30 billion.

Cubist Pharmaceuticals Inc. (NASDAQ: CBST) managed an incredible breakout year as its drugs treat hospital-borne infections, with nearly a 100% share price gain in 2011. The market cap is now about $2.45 billion, and it had nearly $1 billion in cash and liquidity before a recent $221 million acquisition versus about $450 million in long-term debt. Cubist probably could start to pay a dividend if it wants to, but the company has decided to be an acquirer rather than hoarding cash or going defensive. Chances are that it may need to hold on to its cash while it absorbs Adolor and anything else it is considering.

PDL BioPharma, Inc. (NASDAQ: PDLI) has been a dividend payer from its patent royalties, but some payments have been one-time payments until its most recent $0.15 payout for each of the past four quarters. The company also recently forecast a 5% revenue drop and investors are already braced for lower royalty payments. The company recently lost its CFO after only about three years on the job and we really do not like to see CFOs leave biohealth companies. Estimates are $1.18 EPS for 2011 and $1.38 EPS in 2012, but it has about $225 million in cash and liquidity versus a market cap of $867 million. The company may just stick with its current payout structure’s high yield as is until (or if) it can secure another large patent license.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is worth some $5.1 billion or so in market capitalization and is fresh off the news that it settled with Genentech over U.S. opthalmic sales of the eye drug EYLEA with a patent case still brewing, but with Regeneron agreeing to pay out $60 million if sales reach $400 million and it will pay royalties out as well. With cash and liquidity of near $500 million at then end of September we think it is a bit premature to ask this one to start shelling out its cash to shareholders yet, considering it is still expected to have a wide loss in 2012.

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) is so far off of highs now that it seems unlikely investors are expecting much on the dividend front. The company is back on the path of growth after some changes and stumbles, and now its market cap is almost $7 billion. With this one it just feels too soon to expect any dividends in reality. We could analyze all we want, but its new revenue growth is challenged by a cash balance of just over $800 million versus $400 million in long-term debt. What is interesting is that Vertex’s $0.30 EPS expected for 2011 is expected to be $4.55 EPS in 2012. It had a loss of $3.77 EPS in 2010. Maybe after another year or so we can evaluate its future dividend strategy.

After reviewing the great biotech sector’s larger components, it sure does not sound like many other than Biogen Idec Inc. (NASDAQ: BIIB) are really new prime-time dividend candidates for 2012, other than the high payout of PDL BioPharma, Inc. (NASDAQ: PDLI).

JON C. OGG

Filed under: Biotech, Dividend, Drug companies, Healthcare, Shareholder Issues Tagged: ALXN, AMGN, BIIB, CBST, CELG, MRK, PDLI, PFE, REGN, VRTX, VRUS

Top Analyst Upgrades & Downgrades (MO, AVP, CE, LFC, EL, FITB, GE, MIND, VRTX, YHOO, YUM, GRPN)

Administrator — Wed, 14 Dec 2011 14:05:27 +0000

These are some of the top analyst upgrades, downgrades, and initiations seen from Wall Street research calls this Wednesday morning.

Altria Group Inc. (NYSE: MO) Cut to Hold at Stifel Nicolaus.
Avon Products Inc. (NYSE: AVP) Raised to Outperform at BMO Capital Markets.
Celanese Corporation (NYSE: CE) named as Bull of the Day at Zacks Investment Research.
China Life Insurance (NYSE: LFC) maintained as Underperform but named the Bear of the Day by Zacks Investment Research.
Estee Lauder Companies (NYSE: EL) Added to Strong Buy List at Zacks Investment Research.
Fifth Third Bancorp (NASDAQ: FITB) Cut to Market Perform at Bernstein.
General Electric Co. (NYSE: GE) Reiterated Outperform and raised estimates at Credit Suisse.
Mitcham Industries, Inc. (NASDAQ: MIND) named as value stock of the day at Zacks Investment Research.
Vertex Pharmaceuticals (NASDAQ: VRTX) Raised to Outperform but cut the price target to $37 from $39 by Credit Suisse.
Yahoo! Inc. (NASDAQ: YHOO) resumed with a “Sell” rating at Goldman Sachs.
YUM! Brands Inc. (NYSE: YUM) Reiterated Buy and raised price target to $66.00 by Argus.

The big move in the land of stock research and analyst calls is the expiration of the Groupon, Inc. (NASDAQ: GRPN) quiet period. The online social couponing site was initiated in coverage as follows by some of the syndicate firms:

Overweight and $27.00 price target at Barclays;
Buy with $28.00 price target by Bank of America/Merrill Lynch;
Neutral and $24.00 price target at Citigroup;
Neutral with a $25.00 price target at Credit Suisse;
Buy with a $29.00 price target by Goldman Sachs;
Neutral and $24.00 price target at JPMorgan;
Sector Perform with $25.00 price target at RBC Capital Markets.

JON C. OGG

Filed under: Analyst Calls Tagged: AVP, CE, EL, FITB, GE, GRPN, LFC, MIND, MO, VRTX, YHOO, YUM

24/7 Wall St. Top Analyst Calls of the Week (ALU, AMZN, AAPL, CSCO, CSC, CXW, DF, EPD, GNW, GMCR, GRPN, HD, MPEL, PIR, SRDX, TEVA, VRTX, YRCW, ALIM)

Administrator — Sat, 12 Nov 2011 14:19:38 +0000

Each morning 24/7 Wall St. issues a summary list of key analyst upgrades, downgrades, and initiations issued by Wall Street research firms. We review these calls and other calls made throughout the week to see which stand out the most. Some are great calls that were full of insight, while others were total flops. After reviewing and filtering all of these research reports, we end up with the top analyst calls of the week.

We had many key calls that stood out this week in shares of the following: Alcatel-Lucent SA (NYSE: ALU); Amazon.com Inc. (NASDAQ: AMZN); Apple Inc. (NASDAQ: AAPL); Cisco Systems Inc. (NASDAQ: CSCO); Computer Sciences Corporation (NYSE: CSC); Corrections Corporation of America (NYSE:CXW); Dean Foods Company (NYSE: DF); Enterprise Products Partners LP (NYSE: EPD); Genworth Financial Inc. (NYSE: GNW); Green Mountain Coffee Roasters Inc. (NASDAQ: GMCR); Groupon, Inc. (NASDAQ: GRPN); The Home Depot Inc. (NYSE: HD); Melco Crown Entertainment Ltd. (NASDAQ: MPEL); Pier 1 Imports, Inc. (NYSE: PIR); SurModics Inc. (NASDAQ: SRDX); Teva Pharmaceutical Industries (NASDAQ: TEVA); Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX); and YRC Worldwide. Inc. (NASDAQ: YRCW).

We have broken each of these calls out and added in color where applicable.

Alcatel-Lucent SA (NYSE: ALU) can’t get off the floor and it keeps disappointing. Shares even closed at $1.99 after seeing a year low of $1.92 on Friday. Alcatel’s chart looks almost the same as the chart of late-2008, but it cannot blame the market this time. We saw three downgrades worth noting this last week: Cut to Sell at Citigroup; Cut estimates and target at Argus; and Cut to Neutral at BofA/Merrill Lynch.

Amazon.com Inc. (NASDAQ: AMZN) had two big calls this last week. The main call was on Friday when Nomura issued a very unenthusiastic NEUTRAL rating. The other call came on Thursday when Zacks added it to the STRONG SELL list. With valuations still very high and with profit margins running razor-thin, it seems that at least some caution should prevail unless the holiday season is going to blow the doors of the hinges here.

Filed under: Analyst Calls, Research, The Week Tagged: AAPL, ALIM, ALU, AMZN, CSC, CSCO, CXW, DF, EPD, GMCR, GNW, GRPN, HD, MPEL, PIR, SRDX, TEVA, VRTX, YRCW

Top Analyst Upgrades & Downgrades (AAP, AMZN, BUD, CARB, CSCO, CSC, DF, EPD, HSP, KFT, LOGI, NOK, PCG, SD, SPRD, SRDX, VRTX)

Administrator — Thu, 10 Nov 2011 13:35:27 +0000

These are some of Thursday’s top analyst upgrades, downgrades, and initiations seen from Wall Street research calls.

Advance Auto Parts. Inc. (NYSE: AAP) cut to Neutral at Credit Suisse.
Amazon.com Inc. (NASDAQ: AMZN) added to Strong Sell List at Zacks.
Anheuser-Busch InBev (NYSE: BUD) Cut to Neutral at UBS.
Carbonite, Inc. (NASDAQ: CARB) Reiterated Buy with $16 target at Canaccord Genuity.
Cisco Systems Inc. (NASDAQ: CSCO) Raised to Buy at Deutsche Bank; Raised to Buy at Citigroup; Target raised to $26 from $25 at Credit Suisse.
Computer Sciences Corporation (NYSE: CSC) Cut to Underweight at JPMorgan.
Dean Foods Company (NYSE: DF) Cut to Sell at S&P Capital IQ (late-Wednesday); Maintained Buy at Bof A/ML.
Enterprise Products Partners (NYSE: EPD) named Bull of the Day at Zacks.
Hospira, Inc. (NYSE: HSP) named Bear of the Day at Zacks.
Kraft Foods Inc. (NYSE: KFT) Reiterated Buy with $40 target at Argus.
Logitech International SA (NASDAQ: LOGI) Raised to Hold at S&P Capital IQ (late-Wednesday).
Nokia Corporation (NYSE: NOK) maintained Hold with $7.50 target at Canaccord Genuity.
PG&E Corporation (NYSE: PCG) cut to Neutral at Credit Suisse.
SandRidge Energy, Inc. (NYSE: SD) Cut to Neutral at Goldman Sachs.
Spreadtrum Communications Inc. (NASDAQ: SPRD) Reiterated Buy and raised estimates at Canaccord Genuity.
SurModics Inc. (NASDAQ: SRDX) named as Aggressive Growth at Zacks.
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) Raised to Equal-Weight at Morgan Stanley.

JON C. OGG

Filed under: Airlines Tagged: AAP, AMZN, BUD, CARB, CSC, CSCO, DF, EPD, HSP, KFT, LOGI, NOK, PCG, SD, SPRD, SRDX, VRTX

Top Analyst Upgrades & Downgrades (AIXG, ALU, AZN, CXW, EMR, GSK, HON, HUM, KEX, MCHP, OVTI, PAA, RAX, STJ, TEVA, TRMB, VRTX, WFM)

Administrator — Tue, 08 Nov 2011 13:10:26 +0000

These are some of Tuesday’s top analyst upgrades, downgrades, and initiations seen from Wall Street research calls.

Aixtron SE (NASDAQ: AIXG) Raised to Equalweight at Morgan Stanley.
Alcatel-Lucent SA (NYSE: ALU) Cut to Neutral at BofA/ML.
AstraZeneca PLC (NYSE: AZN) Cut to Underweight at Morgan Stanley.
Corrections Corporation of America (NYSE:CXW) named as Value stock of the day at Zacks.
Emerson Electric Co. (NYSE: EMR) Raised to Buy at Citigroup.
GlaxoSmithKline plc (NYSE: GSK) Raised to Equal-Weight at Morgan Stanley.
Honeywell International (NYSE: HON) Raised to Buy at Citigroup.
Humana Inc. (NYSE: HUM) Reiterated Buy and raised target to $95 at Argus.
Kirby Corporation (NYSE: KEX) Started as Outperform at Credit Suisse.
Microchip Technology (NASDAQ: MCHP) named as Bear of the Day at Zacks.
OmniVision Technologies Inc. (NASDAQ: OVTI) Cut to Perform at Oppenheimer.
Plains All American Pipeline, L.P. (NYSE: PAA) Raised to Outperform at Wells Fargo.
Rackspace Hosting, Inc. (NYSE: RAX) Raised to Buy at Kaufman Bros.
St. Jude Medical (NYSE: STJ) Raised to Outperform at Credit Suisse.
Teva Pharmaceutical Industries (NASDAQ: TEVA) Reinstated as Outperform at Credit Suisse.
Trimble Navigation Limited (NASDAQ: TRMB) Started as Buy at Janney.
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) Cut to Neutral at R. W. Baird.
Whole Foods Market Inc. (NYSE: WFM) named Bull of the Day at Zacks.

JON C. OGG

Filed under: Analyst Calls Tagged: AIXG, ALU, AZN, CXW, EMR, GSK, HON, HUM, KEX, MCHP, OVTI, PAA, RAX, STJ, TEVA, TRMB, VRTX, WFM

Vertex RA Study: When Good Is Not Good Enough (VRTX)

Administrator — Mon, 07 Nov 2011 15:04:35 +0000

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) might have sounded as though shares would be up Monday morning if you were just looking at news over the weekend. Instead, shares are down substantially for a day where stocks are up mildly.

The company showed that the final Phase IIa study results of the investigational selective oral JAK3 inhibitor VX-509 showed substantial and statistically significant improvements in multiple measurements of rheumatoid arthritis activity.

The 12-week study met its two primary endpoints of at least a 20% improvement in the signs and symptoms of RA. For the two highest dose groups of the study, statistically significant ACR20, ACR50, ACR70, and DAS28 responses were also observed as compared to placebo, and more than one-third of people in these groups achieved clinical remission (DAS28 remission). Overall, the most frequently reported class of adverse event in the VX-509 and placebo arms was infections. The data from the study will be presented in a poster session on November 8 at the 2011 Annual Meeting for the American College of Rheumatology in Chicago.

This is not coming to market any time soon as more studies await. Vertex said that a six-month Phase IIb study of VX-509 in RA is expected to begin in early 2012 to evaluate once-daily and twice-daily in combination with methotrexate with the study covering approximately 350 people with moderate to severe RA.

Additional secondary endpoints were used to evaluate the clinical activity of VX-509, including ACR50 and ACR70 responses at week 12, DAS28 remission and EULAR response. The responses observed in the two highest dose groups for VX-509 indicated continuous and statistically significant improvements in the signs and symptoms of RA, with these effects being observed in some patients as early as the first week of the study.

At least one analyst wanted more. RBC Capital Markets lowered its rating down to “Sector Perform” from “Outperform” and the new price target was cut to $48 from $49 in the research call.

Vertex shares are down 6.2% at $34.35 after 30 minutes of trading and the 52-week trading range is $32.08 to $58.87.

JON C. OGG

Filed under: Analyst Calls, Biotech Tagged: VRTX

Top Analyst Upgrades & Downgrades (ADTN, BMR, COF, CETV, ERTS, EPB, IDIX, LYG, MMM, NTGR, PLD, PL, SWC, TOL, TSM, VRTX, WSM)

Administrator — Thu, 14 Jul 2011 12:34:26 +0000

These are some of the top analyst upgrades, downgrades, and initiations seen from Wall Street research calls this Thursday morning.

Adtran Inc. (NASDAQ: ADTN) Reiterated Buy with $49 target at Argus.
BioMed Realty (NYSE: BMR) Raised to Buy at Jefferies.
Capital One Financial Corporation (NYSE: COF) Reiterated Sell at Argus.
Central European Media Enterprises Ltd. (NASDAQ: CETV) Started as Underperform at Credit Suisse.
Electronic Arts Inc. (NASDAQ: ERTS) Reiterated Hold at Argus.
El Paso Pipeline Partners, L.P. (NYSE: EPB) Started as Outperform at Credit Suisse.
Idenix Pharmaceuticals Inc. (NASDAQ: IDIX) Started as Neutral at Credit Suisse.
Lloyds Banking Group plc (NYSE: LYG) Raised to Buy at Goldman Sachs.
3M Co. (NYSE: MMM) Cut to Underperform at BofA/ML.
Netgear Inc. (NASDAQ: NTGR) Cut to Equal-Weight at Barclays.
ProLogis (NYSE: PLD) Cut to Underperform at Jefferies.
Protective Life Corp. (NYSE: PL) Raised to Buy at BofA/ML.
Stillwater Mining Co. (NYSE: SWC) Cut to Neutral at JPMorgan.
Toll Brothers Inc. (NYSE: TOL) Raised to Buy at Goldman Sachs.
Taiwan Semiconductor Manufacturing Co. Ltd. (NYSE: TSM) Cut to Neutral at JPMorgan.
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) Started as Underperform at Credit Suisse.
Williams-Sonoma Inc. (NYSE: WSM) Raised to Buy at Goldman Sachs.

You are invited to join our free daily email distribution list to hear more about analyst upgrades and downgrades, top day trader and active trader alerts, dividend trends, news on Buffett and other investment gurus, IPOs, secondary offerings, private equity, and more.

JON C. OGG

Filed under: Analyst Calls Tagged: ADTN, BMR, CETV, COF, EPB, ERTS, IDIX, LYG, MMM, NTGR, PL, PLD, SWC, TOL, TSM, VRTX, WSM

Top Analyst Upgrades & Downgrades (ANF, ALTR, AIG, APA, CIEN, EXPE, LAZ, LDK, MDC, NSM, NVDA, QCOM, URBN, VRTX)

Administrator — Tue, 08 Mar 2011 13:12:23 +0000

These are some of the top analyst upgrades, downgrades, and initiations seen from Wall Street research calls this Tuesday morning.

Abercrombie & Fitch Co. (NYSE: ANF) Raised to Buy at BofA/ML.
Altera Corporation (NASDAQ: ALTR) Reiterated Buy but raised target to $52.50 at Gleacher & Co.

American International Group Inc. (NYSE: AIG) Raised to Outperform as Bull of the Day at Zacks Investment Research.
Apache Corporation (NYSE: APA) Raised to Hold at Argus.
CIENA Corporation (NASDAQ: CIEN) Raised to Neutral at JPMorgan.
Expedia Inc. (NASDAQ: EXPE) Raised to Buy at Citigroup.
Lazard Ltd. (NYSE: LAZ) Reiterated Buy at Argus.
LDK Solar Co., Ltd. (NYSE: LDK) Cut to Sell at Collins Stewart.
MDC Holdings Inc. (NYSE: MDC) Raised to Hold at Credit Suisse.
National Semiconductor (NYSE: NSM) Reiterated Buy with $18 target at Gleacher & Co.
NVIDIA Corporation (NASDAQ: NVDA) Raised to Neutral at JPMorgan.
QUALCOMM Incorporated (NASDAQ: QCOM) Cut to Market Perform at BMO.
Urban Outfitters Inc. (NASDAQ: URBN) Cut to Neutral at SunTrust.
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) Cut to Market Perform at BMO.

You can join our free daily email distribution list to hear more about analyst upgrades and downgrades, top day trader and active trader alerts, dividend trends, news on Buffett and other investment gurus, IPOs, secondary offerings, private equity, and more.

JON C. OGG

Filed under: Analyst Calls Tagged: AIG, ALTR, ANF, APA, CIEN, EXPE, LAZ, LDK, MDC, NSM, NVDA, QCOM, URBN, VRTX